Bone Biologics Corp (BBLG) - Product Pipeline Analysis, 2020 Update

Bone Biologics Corp (Bone Biologics) is a biotechnology company that develops orthobiologic products. It develops NELL-1, a recombinant human protein growth factor, which is essential for normal bone development. It offers bone graft substitutes for spine fusion. Bone Biologics also offers Nell-1/TCP fusion device, which is a single dose vial of Nell-1 recombinant protein freeze dried onto tricalcium phosphate and demineralized bone putty. The companys technology has application in spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicines. It collaborates with manufacturing organizations to develop its products. The company markets its products domestic and internationally. Bone Biologics is headquartered in Burlington, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Bone Biologics Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Bone Biologics Corp Company Overview
Bone Biologics Corp Company Snapshot
Bone Biologics Corp Pipeline Products and Ongoing Clinical Trials Overview
Bone Biologics Corp – Pipeline Analysis Overview
Bone Biologics Corp - Key Facts
Bone Biologics Corp - Major Products and Services
Bone Biologics Corp Pipeline Products by Development Stage
Bone Biologics Corp Ongoing Clinical Trials by Trial Status
Bone Biologics Corp Pipeline Products Overview
NELL-1/DBX Fusion Device
NELL-1/DBX Fusion Device Product Overview
NELL-1/DBX Fusion Device Clinical Trial
NELL-1/DBX Fusion Device - Osteoporosis
NELL-1/DBX Fusion Device - Osteoporosis Product Overview
NELL-1/DBX Fusion Device - Trauma
NELL-1/DBX Fusion Device - Trauma Product Overview
UCS-1
UCS-1 Product Overview
Bone Biologics Corp - Key Competitors
Bone Biologics Corp - Key Employees
Bone Biologics Corp - Locations And Subsidiaries
Head Office
Recent Developments
Bone Biologics Corp, Recent Developments
Jan 07, 2020: Bone Biologics preclinical study shows rhNELL-1 effectively promotes bone formation
Mar 25, 2019: Bone Biologics receives Human Research Ethics Committee (HREC) approval for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX) in Australia
Dec 20, 2017: Bone Biologics: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties
Aug 03, 2017: Bone Biologics Announces Appointment of Bret Hankey to Company’s Board of Director
Jul 06, 2016: Bone Biologics Names Scott D. Boden, MD Chief Medical Advisor
Aug 13, 2015: Bone Biologics Appoints New Chief Executive Officer and a Chief Operating Officer
Dec 09, 2014: Bone Biologics announces appointment of George Oram to its Board of Directors
Nov 12, 2014: Bone Biologics appoints Deina Walsh CFO
Sep 10, 2013: Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
Feb 24, 2009: Bone Biologics Completes Primate Trials Using Recombinant Protein And Demineralized Bone Matrix For Spinal Fusion Surgery
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

Bone Biologics Corp Pipeline Products and Ongoing Clinical Trials Overview
Bone Biologics Corp Pipeline Products by Equipment Type
Bone Biologics Corp Pipeline Products by Indication
Bone Biologics Corp Ongoing Clinical Trials by Trial Status
Bone Biologics Corp, Key Facts
Bone Biologics Corp, Major Products and Services
Bone Biologics Corp Number of Pipeline Products by Development Stage
Bone Biologics Corp Pipeline Products Summary by Development Stage
Bone Biologics Corp Ongoing Clinical Trials by Trial Status
Bone Biologics Corp Ongoing Clinical Trials Summary
NELL-1/DBX Fusion Device - Product Status
NELL-1/DBX Fusion Device - Product Description
NELL-1/DBX Fusion Device - A Multi-center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness of NB1 Bone Graft in Subjects with Degenerative Disc Disease Undergoing Transforaminal Lumbar Interbody Fusion
NELL-1/DBX Fusion Device - Osteoporosis - Product Status
NELL-1/DBX Fusion Device - Osteoporosis - Product Description
NELL-1/DBX Fusion Device - Trauma - Product Status
NELL-1/DBX Fusion Device - Trauma - Product Description
UCS-1 - Product Status
UCS-1 - Product Description
Bone Biologics Corp, Key Employees
Glossary

List Of Figures

Bone Biologics Corp Pipeline Products by Equipment Type
Bone Biologics Corp Pipeline Products by Development Stage
Bone Biologics Corp Ongoing Clinical Trials by Trial Status

Fill The Form For Sample Request

There is no Reviews available